Different Patterns in the Prognostic Value of Age for Breast Cancer-Specific Mortality Depending on Hormone Receptor Status: A SEER Population-Based Analysis

Annals of Surgical Oncology

Volumn 22, Issue 4, 2015, Pages 1102-1110

  Liu, Yi Rong ^a,b   Jiang, Yi Zhou ^a,b   Yu, Ke Da ^a,b   Shao, Zhi Ming ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MARRIAGE; MIDDLE AGED; PATIENT HISTORY OF RADIOTHERAPY; POPULATION RESEARCH; PREDICTION; PROGNOSTIC ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; BREAST NEOPLASMS; CANCER STAGING; METABOLISM; MORTALITY; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; AGE FACTORS; AGED; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SEER PROGRAM; SURVIVAL RATE;

EID: 84925464646     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-4108-5     Document Type: Article

References (31)

1. Ferlay J SI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11, 2013. Retrieved 30 March 2014 at http://globocan.iarc.fr.
2. Tai P, Cserni G, Van De Steene J, et al. Modeling the effect of age in T1-2 breast cancer using the SEER database. BMC Cancer. 2005;5:130.
3. Van de Water W, Markopoulos C, van de Velde CJ, et al. (2012) Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer. JAMA. 307:590–7.
4. Wray CJ, Phatak UR, Robinson EK, et al. The effect of age on race-related breast cancer survival disparities. Ann Surg Oncol. 2013;20:2541–7.
5. Alieldin NH, Abo-Elazm OM, Bilal D, et al. Age at diagnosis in women with nonmetastatic breast cancer: is it related to prognosis? J Egypt Natl Canc Inst. 2014;26:23–30.
6. Ferguson NL, Bell J, Heidel R, et al. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women. Breast J. 2013;19:22–30.
7. Colleoni M, Rotmensz N, Robertson C, et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol. 2002;13:273–9.
8. Han W, Kim SW, Park IA, et al. Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer.2004;4:82.
9. Ihemelandu CU, Leffall LD, Jr., Dewitty RL, et al. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. J Surg Res.2007;143:109–18.
10. Aebi S, Gelber S, Castiglione-Gertsch M, et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet. 2000;355:1869–74.
11. Colleoni M, Rotmensz N, Peruzzotti G, et al. Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node-negative disease. Ann Oncol. 2006;17:1497–503.
12. Ahn SH, Son BH, Kim SW, et al. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea: a report from the Korean Breast Cancer Society. J Clin Oncol. 2007;25:2360–8.
13. Early Breast Cancer Trialists’ Collaborative G, Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–84.
14. Early Breast Cancer Trialists’ Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.
15. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451–67.
16. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003;348:2431–42.
17. Kim EK, Noh WC, Han W, Noh DY. Prognostic significance of young age (<35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based study. World J Surg. 2011;35:1244–53.
18. Roder DM, de Silva P, Zorbas HM, et al. Age effects on survival from early breast cancer in clinical settings in Australia. ANZ J Surg. 2012;82:524–8.
19. Mell LK, Jeong JH, Nichols MA, Polite BN, Weichselbaum RR, Chmura SJ. Predictors of competing mortality in early breast cancer. Cancer. 2010;116:5365–73.
20. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, et al. Overall survival and cause-specific mortality of patients with stage T1a,b N0M0 breast carcinoma. J Clin Oncol. 2007;25:4952–60.
21. Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst. 2000;92:550–6.
22. Bastiaannet E, Liefers GJ, de Craen AJ, et al. Breast cancer in elderly compared to younger patients in the Netherlands: stage at diagnosis, treatment and survival in 127,805 unselected patients. Breast Cancer Res Treat. 2010;124:801–7.
23. Wildiers H, Kunkler I, Biganzoli L, et al. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol. 2007;8:1101–15.
24. White J, Morrow M, Moughan J, et al. Compliance with breast-conservation standards for patients with early-stage breast carcinoma. Cancer. 2003;97:893–904.
25. Giordano SH, Hortobagyi GN, Kau SW, Theriault RL, Bondy ML. Breast cancer treatment guidelines in older women. J Clin Oncol. 2005;23:783–91.
26. Owusu C, Lash TL, Silliman RA. Effect of undertreatment on the disparity in age-related breast cancer-specific survival among older women. Breast Cancer Res Treat. 2007;102:227–36.
27. Pallis AG, Fortpied C, Wedding U, et al. EORTC elderly task force position paper: approach to the older cancer patient. Eur J Cancer. 2010;46:1502–13.
28. Bleyer A, Barr R, Hayes-Lattin B, et al. The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer. 2008;8:288–98.
29. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–30.
30. Lalloo F, Varley J, Moran A, et al. BRCA1, BRCA2, and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer. 2006;42:1143–50.
31. Goldhirsch A, Gelber RD, Yothers G, et al. Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr. 2001;30:44–51.